Effects of vatinoxan in horses sedated with detomidine and butorphanol for gastroscopy: a randomized clinical study.

Vatinoxan attenuates detomidine-induced bradycardia and hyperglycemia in sedated horses.

This randomized clinical trial evaluated vatinoxan, a peripheral alpha2-adrenoceptor antagonist, as an adjunct to detomidine and butorphanol sedation in 22 client-owned horses undergoing gastroscopy. Horses were randomly allocated to receive detomidine (12μg/kg) plus butorphanol (12μg/kg) with or without vatinoxan (200μg/kg). Sedation proved adequate in all horses for the procedure. The vatinoxan group demonstrated significantly preserved heart rate compared to controls, maintained audible borborygmi closer to baseline values, and exhibited attenuated detomidine-induced hyperglycemia through preserved insulin secretion. Blood glucose and serum insulin concentrations remained closer to pre-treatment values in the vatinoxan group. These findings suggest vatinoxan effectively mitigates several side effects associated with alpha2-adrenergic sedatives in equine anesthesia, particularly cardiovascular depression and glucose metabolism alterations. The authors conclude vatinoxan represents a beneficial addition to equine sedation protocols for clinical procedures, improving physiological stability during anesthesia.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.